GlassScriptPhysician profile
Mc Anto Antony
NPI 1639584683
$7,916.06
in general payments reported to CMS, 2019-2025
47 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $690 · 2021: $1,166 · 2022: $1,533 · 2023: $1,792 · 2024: $1,253 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,182 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,182.43 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,195.19 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $569.38 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Novo Nordisk INC | $535.65 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Insulet Corporation | $514.83 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $443.14 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $421.35 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $338.37 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $309.96 | 2019-2024 | Evenity, Prolia, Tepezza |
| Astrazeneca Pharmaceuticals LP | $304.02 | 2019-2022 | |
| Abbvie INC. | $208.73 | 2019-2025 | Synthroid |
| Ascendis Pharma Endocrinology INC | $196.52 | 2023-2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $189.52 | 2020-2025 | Strensiq |
| Dexcom, INC. | $187.20 | 2021-2025 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $181.18 | 2022-2024 | Tirosint, Licart, Tirosint |
| Abbott Laboratories | $180.74 | 2021-2025 | Freestyle Libre 3 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $176.05 | 2020-2025 | Signifor Lar, Isturisa |
| Almatica Pharma LLC | $172.02 | 2024-2025 | Teriparatide |
| Novartis Pharmaceuticals Corporation | $167.95 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $160.53 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.36 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Medtronic, INC. | $133.41 | 2021-2025 | Minimed 780g |
| Radius Health, INC. | $123.12 | 2024-2025 | Tymlos |
| Antares Pharma, INC. | $120.18 | 2020-2023 | Xyosted, Tlando, Nocdurna |
| Corcept Therapeutics | $120.15 | 2020-2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $111.26 | 2021-2023 | |
| Mannkind Corporation | $77.25 | 2023 | Afrezza |
| Ascensia Diabetes Care US INC. | $70.90 | 2023-2024 | |
| Clarus Therapeutics INC. | $70.78 | 2021 | |
| Esperion Therapeutics, INC. | $49.38 | 2021-2025 | Nexletol |
| Horizon Therapeutics Plc | $48.80 | 2021-2022 | |
| Becton, Dickinson and Company | $43.55 | 2021-2022 | |
| Zealand Pharma US, INC. | $39.01 | 2021 | |
| Amryt Pharma Holdings LTD | $38.72 | 2022-2023 | Myalept |
| Kyowa Kirin, INC. | $27.80 | 2023 | Crysvita |
| Cequr Corporation | $26.49 | 2022-2023 | Cequr Simplicity |
| Beta Bionics, INC. | $25.40 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Nevro Corp. | $24.52 | 2022 | |
| Sequel Med Tech, LLC | $23.59 | 2025 | Twiist |
| Amneal Pharmaceuticals LLC | $22.32 | 2022 | |
| Verity Pharmaceuticals INC. | $20.49 | 2025 | Tlando |
| Renalytix Ai, INC. | $19.28 | 2022 | |
| Shire North American Group INC | $15.83 | 2019 | |
| Eusa Pharma (US) LLC | $15.23 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.45 | 2022 | |
| Tolmar, INC. | $13.88 | 2023 | |
| Medtronic Minimed, INC. | $13.35 | 2020 | |
| Tetraphase Pharmaceuticals, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mc Anto Antony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.